OBJECTIVES : In China pregabalin is the only one drug with Fibromyalgia (FM) indication approved China National Medical Products Administration (NMPA). While in clinical practice duloxetine are still often prescribed in FM treatment in China.This study is to adapt a developed FM pharmacoeconomics model to evaluate the cost-effectiveness of pregabalin compared with duloxetine by using Chinese data.

METHODS : A decision analytic model of cost and outcomes based on RCTs has been developed in 2010.Costs considered in this model included: drugs utilization, GP visits, diagnostic tests and referrals to specialists. Costs are presented in 2019 RMB. Outcomes considered are QALY gain and responder months. Treatment comparators and utilization patterns were provided through local physician questionnaires or internal dataset review. Fibromyalgia patients' health resources utilization rates and costs were localized by literature review, official health information platform search as well as internal data source analysis. China life tables data was provided by WHO. 3.5% was applied as the discount rate.

RESULTS : According to a 3-years simulation, compared pregabalin 300mg with duloxetine 60mg, the incremental cost was 8,804.08RMB, the incremental responders were 5. The ICER(per QALY) would be 169,305.18RMB, which is less than 3 GDPs per capita (64644RMB *3). One way sensitive analysis (OWSA) showed

CONCLUSIONS : Pregabalin may be cost-effective compared with Duloxetine in China health care setting.